Literature DB >> 2173767

Equine infectious anemia virus derived from a molecular clone persistently infects horses.

L Whetter1, D Archambault, S Perry, A Gazit, L Coggins, A Yaniv, D Clabough, J Dahlberg, F Fuller, S Tronick.   

Abstract

A full-length molecular clone of equine infectious anemia virus (EIAV) was isolated from a persistently infected canine fetal thymus cell line (Cf2Th). Upon transfection of equine dermis cells, the clone, designated CL22, yielded infectious EIAV particles (CL22-V) that replicated in vitro in both Cf2Th cells and an equine dermis cell strain. Horses infected with CL22-V developed an antibody response to viral proteins and possessed viral DNA in peripheral blood mononuclear cells, as determined by polymerase chain reaction assays. In addition, horses infected with CL22-V became persistently infected and were capable of transmitting the infection by transfer of whole blood to uninfected horses. However, CL22-V, like the parental canine cell-adapted virus, did not cause clinical signs in infected horses. Reverse transcriptase assays of CL22-V- and virulent EIAV-infected equine mononuclear cell cultures indicated that the lack of virulence of CL22-V was not due to an inability to infect and replicate in equine mononuclear cells in vitro.

Entities:  

Mesh:

Year:  1990        PMID: 2173767      PMCID: PMC248720          DOI: 10.1128/JVI.64.12.5750-5756.1990

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Responses in horses infected with equine infectious anemia virus adapted to tissue culture.

Authors:  D E Gutekunst; C S Becvar
Journal:  Am J Vet Res       Date:  1979-07       Impact factor: 1.156

2.  Equine infectious anemia: current knowledge.

Authors:  C J Issel; L Coggins
Journal:  J Am Vet Med Assoc       Date:  1979-04-01       Impact factor: 1.936

3.  Scanning and transmission electron microscopic study of equine infectious anemia virus.

Authors:  M A Gonda; H P Charman; J L Walker; L Coggins
Journal:  Am J Vet Res       Date:  1978-05       Impact factor: 1.156

4.  Production of equine infectious anemia antigen in a persistently infected cell line.

Authors:  W A Malmquist; D Barnett; C S Becvar
Journal:  Arch Gesamte Virusforsch       Date:  1973

5.  Titration of equine infectious anemia virus. Effect of dosage on incubation time and clinical signs.

Authors:  L J Kemeny; L O Mott; J E Pearson
Journal:  Cornell Vet       Date:  1971-10

6.  Immunofluorescent localization of equine infectious anemia virus in tissue.

Authors:  T C McGuire; T B Crawford; J B Henson
Journal:  Am J Pathol       Date:  1971-02       Impact factor: 4.307

7.  Antigenic drift of equine infectious anemia virus in chronically infected horses.

Authors:  Y Kono; K Kobayashi; Y Fukunaga
Journal:  Arch Gesamte Virusforsch       Date:  1973

8.  Equine infectious anemia virus: evidence favoring classification as a retravirus.

Authors:  H P Charman; S Bladen; R V Gilden; L Coggins
Journal:  J Virol       Date:  1976-09       Impact factor: 5.103

9.  Characterization of RNA from equine infectious anemia virus.

Authors:  W P Cheevers; B G Archer; T B Crawford
Journal:  J Virol       Date:  1977-11       Impact factor: 5.103

10.  RNA-dependent DNA polymerase associated with equine infectious anemia virus.

Authors:  B G Archer; T B Crawford; T C McGuire; M E Frazier
Journal:  J Virol       Date:  1977-04       Impact factor: 5.103

View more
  15 in total

1.  Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro.

Authors:  A Engelman; R Craigie
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro.

Authors:  S T Perry; M T Flaherty; M J Kelley; D L Clabough; S R Tronick; L Coggins; L Whetter; C R Lengel; F Fuller
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

3.  Characterization of equine infectious anemia virus dUTPase: growth properties of a dUTPase-deficient mutant.

Authors:  D S Threadgill; W K Steagall; M T Flaherty; F J Fuller; S T Perry; K E Rushlow; S F Le Grice; S L Payne
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

4.  Immune-mediated thrombocytopenia in horses infected with equine infectious anemia virus.

Authors:  D L Clabough; D Gebhard; M T Flaherty; L E Whetter; S T Perry; L Coggins; F J Fuller
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Evolution of the equine infectious anemia virus long terminal repeat during the alteration of cell tropism.

Authors:  Wendy Maury; Robert J Thompson; Quentin Jones; Sarahann Bradley; Tara Denke; Prasith Baccam; Matthew Smazik; J Lindsay Oaks
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Wild-type equine infectious anemia virus replicates in vivo predominantly in tissue macrophages, not in peripheral blood monocytes.

Authors:  D C Sellon; S T Perry; L Coggins; F J Fuller
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

7.  Equine infectious anemia virus replication is upregulated during differentiation of blood monocytes from acutely infected horses.

Authors:  D C Sellon; K M Walker; K E Russell; S T Perry; P Covington; F J Fuller
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

8.  Characterization of the minimal DNA-binding domain of the HIV integrase protein.

Authors:  R A Lutzke; C Vink; R H Plasterk
Journal:  Nucleic Acids Res       Date:  1994-10-11       Impact factor: 16.971

9.  Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus.

Authors:  Susan L Payne; Xiao-fang Pei; Bin Jia; Angela Fagerness; Frederick J Fuller
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

10.  Genomic variation and segregation of equine infectious anemia virus during acute infection.

Authors:  C H Kim; J W Casey
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.